Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer.

The article presents the discussion on assessing the direct costs of the association of radiotherapy (RT) to immunotherapy (IT) in cancer patients. Topics include effects of ionizing radiation being recognized as contributing to systemic antitumor immunity; and bias being minimized by the use of the same comparator pembrolizumab in all trials.